| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
TPABr does not have a defined pharmacological target as it is a phase transfer catalyst and chemical reagent. The compound facilitates reactions between reagents that would otherwise be immiscible, improving reaction efficiency and selectivity. It is widely utilized in organic chemistry, especially in nucleophilic substitutions, and is also involved in the synthesis of zeolites and other materials. Its primary applications are in organic synthesis and materials science.
|
|---|---|
| ln Vitro |
No specific in vitro pharmacological activity data are available for TPABr as it is a chemical reagent. In research settings, the compound is used as a phase transfer catalyst and surfactant. Its activity is assessed in terms of catalytic efficiency and phase transfer ability rather than direct biological activity. The compound is used in the synthesis of ZSM-5 zeolite.
|
| ln Vivo |
No specific in vivo pharmacological activity data have been documented for TPABr as it is not a therapeutic agent. The compound is used exclusively as a chemical reagent and phase transfer catalyst. It is not administered to animals for pharmacological evaluation. Its applications are limited to organic synthesis and materials research.
|
| Enzyme Assay |
For non-cellular assays, TPABr is characterized by standard analytical techniques including NMR, HPLC, and elemental analysis to confirm identity and purity. Purity is typically ≥95% to 99%. The compound is soluble in water (100 g/l) and chloroform. It has a melting point of 266-272°C. Storage: store below +30°C. The compound is hygroscopic.
|
| Cell Assay |
For in vitro cell-based studies, TPABr is not typically used as a direct test compound. It is a chemical reagent for synthetic chemistry applications. If handled in a biological laboratory context, appropriate safety precautions should be taken due to the quaternary ammonium structure. The compound is a solid at room temperature.
|
| Animal Protocol |
For in vivo animal studies, TPABr is not typically administered as a test compound. It is used as a chemical reagent and phase transfer catalyst. If used in toxicological studies, it would be administered via appropriate routes with suitable formulations. Standard animal welfare guidelines should be followed.
|
| ADME/Pharmacokinetics |
TPABr has a molecular weight of 266.26 and formula C₁₂H₂₈BrN. It has a melting point of 266-272°C. Solubility: soluble in water (100 g/l) and chloroform. Storage: store below +30°C. The compound is hygroscopic and appears as colorless or white crystals. Purity: typically ≥95% to 99%.
|
| Toxicity/Toxicokinetics |
TPABr is for research use only and not for human consumption. Standard laboratory safety practices should be followed when handling this chemical. Quaternary ammonium compounds can be irritating to skin, eyes, and mucous membranes. Appropriate personal protective equipment including gloves and safety glasses should be worn. The compound has刺激性.
|
| Additional Infomation |
Tetrapropylammonium bromide is a white to off-white crystalline solid. (NTP, 1992)
Tetrapropylammonium bromide is a quaternary ammonium bromide salt with four propyl substituents surrounding the nitrogen atom at the cation center. It is a potassium channel blocker. It is both a bromide salt and a quaternary ammonium salt. It contains a tetrapropylammonium group. TPABr (CAS 1941-30-6) is also known as tetrapropylammonium bromide, tetra-n-propylammonium bromide, and 1-propanaminium, N,N,N-tripropyl-, bromide. It is commonly used as a phase transfer catalyst in organic synthesis and in the synthesis of zeolites. No clinical trials or therapeutic approvals exist. |
| Molecular Formula |
C12H28BRN
|
|---|---|
| Molecular Weight |
266.26
|
| Exact Mass |
265.14
|
| CAS # |
1941-30-6
|
| PubChem CID |
74745
|
| Appearance |
White to off-white solid powder
|
| Melting Point |
486 °F (NTP, 1992)
|
| LogP |
0.447
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
14
|
| Complexity |
80.2
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[Br-].[N+](C([H])([H])C([H])([H])C([H])([H])[H])(C([H])([H])C([H])([H])C([H])([H])[H])(C([H])([H])C([H])([H])C([H])([H])[H])C([H])([H])C([H])([H])C([H])([H])[H]
|
| InChi Key |
BGQMOFGZRJUORO-UHFFFAOYSA-M
|
| InChi Code |
InChI=1S/C12H28N.BrH/c1-5-9-13(10-6-2,11-7-3)12-8-4;/h5-12H2,1-4H3;1H/q+1;/p-1
|
| Chemical Name |
tetrapropylazanium;bromide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (375.57 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2 mg/mL (7.51 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2 mg/mL (7.51 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2 mg/mL (7.51 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.7557 mL | 18.7786 mL | 37.5573 mL | |
| 5 mM | 0.7511 mL | 3.7557 mL | 7.5115 mL | |
| 10 mM | 0.3756 mL | 1.8779 mL | 3.7557 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
